[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361906-105":59,"doc-detail-361906-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","8c7-a-fully-human-anti-ptgfrn-monoclonal-antibody-drug-conjugate-inhibiting-tumour-growth-of-mesothelioma-and-paediatric-medulloblastoma-cell-lines","8C7: A Fully Human Anti-PTGFRN Monoclonal Antibody-Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines","","Antibody-Drug Conjugates (ADCs) enable cancer-targeted therapy by coupling a monoclonal antibody to a cytotoxic payload for selective delivery. This work evaluates PTGFRN as an internalising cell-surface target and screens tissue sections to define PTGFRN expression. Fully human hybridoma lines generating antibodies against the PTGFRN extracellular domain were produced, including the IgG1 clone 8C7. Duocarmycin was conjugated to 8C7 to form a potent 8C7-ADC with strong in vitro and in vivo activity in PTGFRN-expressing models, while lacking effects in PTGFRN-negative cells. In xenografted athymic mice, intraperitoneal 8C7-ADC inhibited tumour formation and growth without altering body or organ weights, supporting PTGFRN-directed ADC development for cancers with unmet needs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/8c7-a-fully-human-anti-ptgfrn-monoclonal-antibody-drug-conjugate-inhibiting-tumour-growth-of-mesothelioma-and-paediatric-medulloblastoma-cell-lines/361906/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/8c7-a-fully-human-anti-ptgfrn-monoclonal-antibody-drug-conjugate-inhibiting-tumour-growth-of-mesothelioma-and-paediatric-medulloblastoma-cell-lines/361906.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic strategy evaluated in this study?","Question",{"text":112,"@type":113},"The study evaluates an antibody-drug conjugate approach that uses an internalising monoclonal antibody to deliver a cytotoxic payload directly to cancer cells expressing PTGFRN.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the PTGFRN target assessed and selected for ADC development?",{"text":117,"@type":113},"PTGFRN expression was assessed using immunohistochemistry across tissue sections, and a fully human antibody producing hybridoma targeting the PTGFRN extracellular domain was developed.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the 8C7-ADC perform in vitro and in vivo?",{"text":121,"@type":113},"The conjugate showed high potency in in vitro and in vivo models for PTGFRN-expressing cell lines, inhibited tumour formation and growth in xenografted mice, and had no effect on PTGFRN-negative MDA-MB-231, with no body or organ weight changes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361906,1790194507,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Journal of Cellular and Molecular Medicine  \nORIGINAL ARTICLE  OPEN ACCESS   \n8C7: A Fully Human Anti-PTGFRN Monoclonal Antibody-Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines  \nJorge Marquez1,2 | Jianping Dong2 | Binbin Yue2 | Jun Hayashi3 | Chun Dong3 | Mitsuo Oshimura4 | Ginette Serrero2,3   \n1Department of Pharmaceutical Sciences, University of Maryland, Baltimore School of Pharmacy, Baltimore, Maryland, USA | 2Target Discovery Division, A&G Pharmaceutical, Inc. , Columbia, Maryland, USA | 3Precision Antibody, Columbia, Maryland, USA | 4Trans Chromosomics, Inc. Yonago, Tottori, Japan  \nCorrespondence: Ginette Serrero ([gserrero@agpharma.com](gserrero@agpharma.com))  \nReceived: 5 May 2025 | Revised: 23 May 2025 | Accepted: 2 June 2025  \nFunding: Funded in part by National Cancer Institute grant R44CA162729 to G.S.  \nKeywords: antibody-drug conjugate | medulloblastoma | mesothelioma | PTGFRN | xenograft  \nABSTRACT  \nAntibody Drug Conjugates (ADCs) are attractive for developing cancer-targeted therapies, particularly for cancers with unmet needs. Identification of a druggable internalising cell-surface target enables the development of internalising monoclonal antibodies to deliver toxic payloads directly to the cancer cells. Using immunohistochemistry, we screened various non-cancerous and cancerous tissue sections to assess PTGFRN expression levels. We produced hybridoma lines that produce fully human antibodies against the PTGFRN extracellular domain. After screening, we conjugated the cytotoxic payload Duocarmycin to an antibody candidate and tested its efficacy in in vitro assays, as well as in vivo xenografted athymic nude mice. We showed that PTGFRN expression was undetectable in non-cancerous tissue samples and overexpressed in several patient-derived cancer tissue samples. We produced a hybridoma line that produces a fully human IgG1 (8C7) against PTGFRN. 8C7 binds to cell-surface PTGFRN, inducing endocytosis of PTGFRN. Direct conjugation of Duocarmycin to 8C7 resulted in an antibody-drug conjugate that showed high potency in in vitro and in vivo models for three PTGFRN-expressing cell lines examined, A431, DAOY, and MSTO, while it had no effect on PTGFRN-negative MDA-MB-231. 8C7-ADC administered via intraperitoneal injection to xenografted mice showed inhibition of tumour formation and growth with no effect on body weight and organ weights. These findings further validate PTGFRN as a target for antibody-drug conjugate development for cancers with unmet needs.  \n1 | Introduction  \nIn oncology, Antibody-Drug Conjugates (ADCs) have gained academic, regulatory, and industry attention due to their highly specified targeting capability, high tissue specificity, low offtarget effects, and ability to be conjugated to a variety of potent  \npayloads [1] . ADCs are comprised of a monoclonal antibody recognising a unique cell-surface antigen, a bridging chemical linker, and a cytotoxic drug payload. The large selection of linkers and payloads has the potential to be mixed and matched in order to optimise efficacy and minimise off-target toxicity of the resulting ADC [2] .  \n\n| Abbreviations: ADC, Antibody-Drug Conjugate; BLI, Biolayer interferometry; DAR, drug antibody ratio; HIC, Hydrophobic Interaction Chromatography; IHC, Immunohistochemistry; MPM, Malignant Pleural Mesothelioma; OS, Overall Survival; PEG, Polyethylene Glycol; PFS, Progression-Free Survival; PTGFRN, Prostaglandin F2 Receptor Negative; SD, Standard Deviation; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TMA, Tissue microarray; TME, Tumour Microenvironment. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2025 A&G Pharmaceutical, Inc. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Mo","cbCaiojBbldN7KXa","https://ap.wps.com/l/cbCaiojBbldN7KXa","pdf",1121391,12,"English","# Introduction\n## ADC Targeting Concepts\n## Linkers and Payload Selection\n## Target Identification Rationale","[{\"question\":\"What is the main therapeutic strategy evaluated in this study?\",\"answer\":\"The study evaluates an antibody-drug conjugate approach that uses an internalising monoclonal antibody to deliver a cytotoxic payload directly to cancer cells expressing PTGFRN.\"},{\"question\":\"How was the PTGFRN target assessed and selected for ADC development?\",\"answer\":\"PTGFRN expression was assessed using immunohistochemistry across tissue sections, and a fully human antibody producing hybridoma targeting the PTGFRN extracellular domain was developed.\"},{\"question\":\"How did the 8C7-ADC perform in vitro and in vivo?\",\"answer\":\"The conjugate showed high potency in in vitro and in vivo models for PTGFRN-expressing cell lines, inhibited tumour formation and growth in xenografted mice, and had no effect on PTGFRN-negative MDA-MB-231, with no body or organ weight changes.\"}]","8C7: A Fully Human Anti-PTGFRN Monoclonal Antibody-Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines | PDF",1790145949,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/953bda2ae5b35aeb0384ffe33999350b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a76fe124de57ffe5413d720e1b1dce84.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdde5e07651766afd0745e432c7988d6.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfd781309476fa84099030d26dbd318e.webp",980,1287]